Resistance is not futile: treatment-refractory schizophrenia – overview, evaluation and treatment

References

• McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76.
   PubMed Web of Science ®Google Scholar
• Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012 Dec 15;380(9859):2163–2196.
   PubMed Web of Science ®Google Scholar
• Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007 Oct;64(10):1123–1131.
   PubMed Web of Science ®Google Scholar
• Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the global burden of disease study 2010. Lancet. 2012 Dec 15;380(9859):2129–2143.
   PubMed Web of Science ®Google Scholar
• Reichenberg A, Feo C, Prestia D, et al. The course and correlates of everyday functioning in schizophrenia. Schizophr Res Cogn. 2014 Mar 1;1(1):e47–e52.
   PubMedGoogle Scholar
• Elkis H, Buckley PF. Treatment-resistant schizophrenia. Psychiatr Clin North Am. 2016 Jun;39(2):239–265.
   PubMed Web of Science ®Google Scholar
• Citrome L. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. J Clin Psychiatry. 2014;75(Suppl 1):21–26.
   PubMed Web of Science ®Google Scholar
• Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs. 2013 Nov;27(11):879–911.
   PubMed Web of Science ®Google Scholar
• Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol. 2015 Feb;29(2):97–115.
   PubMed Web of Science ®Google Scholar
• Tracy DK, Shergill S. Treatment-refractory schizophrenia: definition and assessment. In: Buckley PF, Gaughran F, editors. Treatment-refractory schizophrenia—a clinical conundrum. Heildelberg (Germany): Springer; 2014. p. 1–19.
   Google Scholar
• Emsley R, Chiliza B, Asmal L, et al. The concepts of remission and recovery in schizophrenia. Curr Opin Psychiatry. 2011 Mar;24(2):114–121.
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic double-blind comparison with chlorpromazine . Arch Gen Psychiatry. 1988 Sep;45(9):789–796.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Remington G, Mulsant BH, et al. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res. 2012 May 15;197(1–2):1–6.
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. American Psychiatric Association, steering committee on practice guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004 Feb;161(2 Suppl):1–56.
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Kreyenbuhl J, Kelly DL, et al. Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010 Jan;36(1):71–93.
   PubMed Web of Science ®Google Scholar
• Moore TA, Buchanan RW, Buckley PF, et al. The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007 Nov;68(11):1751–1762.
   PubMed Web of Science ®Google Scholar
• The International Psychopharmacology Algorithm Project, 2016. cited. [cited 2018 Aug 9]. Available from: http://www.ipap.org
   Google Scholar
• National Institute for Health and Care Excellence (NICE): Psychosis and schizophrenia in adults: prevention and management (NICE guideline CG178). London: Feb 12, 2014 cited [Accessed 2018 Aug 9]. Available from: http://www.nice.org.uk/guidance/cg178
   Google Scholar
• Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) task force on treatment guidelines for schizophrenia. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012 Jul;13(5):318–378.
   PubMed Web of Science ®Google Scholar
• Barnes TR. Schizophrenia consensus group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011 May;25(5):567–620.
   PubMed Web of Science ®Google Scholar
• Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017 Mar 1;174(3):216–229.
   PubMed Web of Science ®Google Scholar
• Samara MT, Leucht C, Leeflang MM, et al. Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry. 2015 Jul;172(7):617–629.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 Sep 22;353(12):1209–1223.
   PubMed Web of Science ®Google Scholar
• Citrome L. Handbook of treatment-resistant schizophrenia. LondonUK: Springer Healthcare; 2013.
   Google Scholar
• Leucht S, Samara M, Heres S, et al. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull. 2014 Mar;40(2):314–326.
   PubMed Web of Science ®Google Scholar
• Leucht S, Samara M, Heres S, et al. Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull. 2015 Nov;41(6):1397–1402.
   PubMed Web of Science ®Google Scholar
• Leucht S, Samara M, Heres S, et al. Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull. 2016 Jul;42(Suppl 1):S90–4.
   PubMedGoogle Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.
   PubMed Web of Science ®Google Scholar
• Alphs LD, Summerfelt A, Lann H, et al. The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull. 1989;25(2):159–163.
   PubMed Web of Science ®Google Scholar
• Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008 Feb;165(2):203–213.
   PubMed Web of Science ®Google Scholar
• Morosini PL, Magliano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV social and occupational functioning assessment scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000 Apr;101(4):323–329.
   PubMed Web of Science ®Google Scholar
• Patterson TL, Goldman S, McKibbin CL, et al. UCSD performance-based skills assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull. 2001;27(2):235–245.
   PubMed Web of Science ®Google Scholar
• Citrome L, Bilder RM, Volavka J. Managing treatment-resistant schizophrenia: evidence from randomized clinical trials. J Psychiatr Pract. 2002 Jul;8(4):205–215.
   PubMedGoogle Scholar
• Kantrowitz JT. Managing negative symptoms of schizophrenia: how far have we come? CNS Drugs. 2017 May;31(5):373–388.
   PubMed Web of Science ®Google Scholar
• Kurtz MM. Symptoms versus neurocognitive skills as correlates of everyday functioning in severe mental illness. Expert Rev Neurother. 2006 Jan;6(1):47–56.
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
   Google Scholar
• Lally J, Ajnakina O, Di Forti M, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med. 2016 Nov;46(15):3231–40. A.
   PubMed Web of Science ®Google Scholar
• Gillespie AL, Samanaite R, Mill J, et al. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review. BMC Psychiatry. 2017 Jan 13;17(1):12,016–1177-y.
   PubMedGoogle Scholar
• Demjaha A, Murray RM, McGuire PK, et al. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012 Nov;169(11):1203–1210.
   PubMed Web of Science ®Google Scholar
• Demjaha A, Egerton A, Murray RM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014 Mar 1;75(5):e11–3.
   PubMed Web of Science ®Google Scholar
• Perkins DO, Gu H, Boteva K, et al. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005 Oct;162(10):1785–1804.
   PubMed Web of Science ®Google Scholar
• Harris MG, Henry LP, Harrigan SM, et al. The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. Schizophr Res. 2005 Nov 1;79(1):85–93.
   PubMed Web of Science ®Google Scholar
• Lieberman JA. Neuroprotection: a new strategy in the treatment of schizophrenia neurobiological basis of neurodegeneration and neuroprotection. CNS Spectr. 2007 Oct;12(10 Suppl 18):4–6.
   PubMedGoogle Scholar
• Dammak M. Treatment-resistant schizophrenia: prevalence and risk factors. In: Woolfolk R, Allen L, editors. Mental disorders theoretical and empirical perspectives. Rijeka (Croatia): InTech; 2013. p. 1–22.
   Google Scholar
• Wimberley T, Stovring H, Sorensen HJ, et al. Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. Lancet Psychiatry. 2016 Apr;3(4):358–366.
   PubMed Web of Science ®Google Scholar
• Bobo W, Meltzer H. Duration of untreated psychosis and premorbid function: relationship with treatment response and treatment-resistant schizophrenia. In: Elkis H, Meltzer H, editors. Therapy- resistant schizophrenia. Basel (Switzerland): Karger; 2010. p. 74–86.
   Google Scholar
• Lieberman JA, Alvir JM, Koreen A, et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology. 1996 Mar;14(3 Suppl):13S–21S.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996;57(Suppl 9):5–9.
   PubMed Web of Science ®Google Scholar
• Curson DA, Barnes TR, Bamber RW, et al. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the medical research council fluphenazine/placebo trial III. relapse postponement or relapse prevention? The implications for long-term outcome. Br J Psychiatry. 1985;146:474–480.
   PubMed Web of Science ®Google Scholar
• Wiersma D, Nienhuis FJ, Slooff CJ, et al. Natural course of schizophrenic disorders: a 15-year followup of a dutch incidence cohort. Schizophr Bull. 1998;24(1):75–85.
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry. 1991 Aug;48(8):739–745.
   PubMedGoogle Scholar
• Agid O, Arenovich T, Sajeev G, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011 Nov;72(11):1439–1444.
   PubMed Web of Science ®Google Scholar
• Kolakowska T, Williams AO, Ardern M, et al. Schizophrenia with good and poor outcome. I: early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry. 1985;146:229–239.
   PubMed Web of Science ®Google Scholar
• Emsley R, Nuamah I, Hough D, et al. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr Res. 2012 Jun;138(1):29–34.
   PubMed Web of Science ®Google Scholar
• Albus M, Hubmann W, Mohr F, et al. Neurocognitive functioning in patients with first-episode schizophrenia: results of a prospective 5-year follow-up study. Eur Arch Psychiatry Clin Neurosci. 2006 Oct;256(7):442–451.
   PubMed Web of Science ®Google Scholar
• Zipursky RB, Reilly TJ, Murray RM. The myth of schizophrenia as a progressive brain disease. Schizophr Bull. 2013 Nov;39(6):1363–1372.
   PubMed Web of Science ®Google Scholar
• Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002 Oct;63(10):892–909.
   PubMed Web of Science ®Google Scholar
• Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002 Dec;63(12):1121–1128.
   PubMed Web of Science ®Google Scholar
• Weiden P, Rapkin B, Zygmunt A, et al. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv. 1995 Oct;46(10):1049–1054.
   PubMed Web of Science ®Google Scholar
• Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013 Oct;12(3):216–226.
   PubMed Web of Science ®Google Scholar
• Lincoln TM, Lullmann E, Rief W. Correlates and long-term consequences of poor insight in patients with schizophrenia. Sys Rev Schizophr Bull. 2007 Nov;33(6):1324–1342.
   PubMed Web of Science ®Google Scholar
• Czobor P, Van Dorn RA, Citrome L, et al. Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol. 2015 Aug;25(8):1158–1166.
   PubMed Web of Science ®Google Scholar
• McCutcheon R, Beck K, Bloomfield MA, et al. Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. J Psychopharmacol. 2015 Aug;29(8):892–897.
   PubMed Web of Science ®Google Scholar
• Velligan DI, Lam YW, Glahn DC, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull. 2006 Oct;32(4):724–742.
   PubMed Web of Science ®Google Scholar
• Kennedy WK, Jann MW, Kutscher EC. Clinically significant drug interactions with atypical antipsychotics. CNS Drugs. 2013 Dec;27(12):1021–1048.
   PubMed Web of Science ®Google Scholar
• Greenberg WM, Citrome L. Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature. Clin Pharmacokinet. 2017 May;56(5):493–503.
   PubMed Web of Science ®Google Scholar
• Citrome L. Using oral ziprasidone effectively: the food effect and dose-response. Adv Ther. 2009 Aug;26(8):739–748.
   PubMed Web of Science ®Google Scholar
• Lally J, Gaughran F, Timms P, et al. Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics. Pharmgenomics Pers Med. 2016 Nov;7(9):117–129.
   Google Scholar
• Goldberg JF. Do you order pharmacogenetic testing? why? J Clin Psychiatry. 2017 Sep/Oct;78(8):1155–1156.
   PubMed Web of Science ®Google Scholar
• Ravyn D, Ravyn V, Lowney R, et al. CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence. Schizophr Res. 2013 Sep;149(1–3):1–14.
   PubMed Web of Science ®Google Scholar
• Lindenmayer J, Khan A. Assessment of therapy-resistant schizophrenia. In: Elkis H, Meltzer H, editors. Therapy-resistant schizophrenia. Basel (Switzerland): Karger; 2010. p. 9–32.
   Google Scholar
• Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the epidemiologic catchment area (ECA) study. JAMA. 1990 Nov 21;264(19):2511–2518.
   PubMed Web of Science ®Google Scholar
• Lybrand J, Caroff S. Management of schizophrenia with substance use disorders. Psychiatr Clin North Am. 2009 Dec;32(4):821–833.
   PubMed Web of Science ®Google Scholar
• Van Dorn RA, Desmarais SL, Scott Young M, et al. Assessing illicit drug use among adults with schizophrenia. Psychiatry Res. 2012 Dec 30;200(2–3):228–236.
   PubMed Web of Science ®Google Scholar
• Kerfoot KE, Rosenheck RA, Petrakis IL, et al. CATIE investigators. Substance use and schizophrenia: adverse correlates in the CATIE study sample. Schizophr Res. 2011 Nov;132(2–3):177–182.
   PubMed Web of Science ®Google Scholar
• Citrome L. Treatment-refractory schizophrenia: what is it & what has been done about it? Neuropsychiatry. 2011;1(4):325–347.
   Google Scholar
• Samara MT, Dold M, Gianatsi M, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016 Mar;73(3):199–210.
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003 Jun;60(6):553–564.
   PubMed Web of Science ®Google Scholar
• Leucht S, Arbter D, Engel RR, et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009 Apr;14(4):429–447.
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009 Jan 3;373(9657):31–41.
   PubMed Web of Science ®Google Scholar
• Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009 Feb;166(2):152–163.
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013 Sep 14;382(9896):951–962.
   PubMed Web of Science ®Google Scholar
• Kane JM, Potkin SG, Daniel DG, et al. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. J Clin Psychiatry. 2011;72(2):194–204.
   PubMed Web of Science ®Google Scholar
• Ermilov M, Gelfin E, Levin R, et al. A pilot double-blind comparison of d-serine and high-dose olanzapine in treatment-resistant patients with schizophrenia. Schizophr Res. 2013;150(2–3):604–605.
   PubMed Web of Science ®Google Scholar
• Schooler NR, Marder SR, Chengappa KN, et al. Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. J Clin Psychiatry. 2016 May;77(5):628–634.
   PubMed Web of Science ®Google Scholar
• Muscatello MRA, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res. 2011;127(1–3):93–99.
   PubMed Web of Science ®Google Scholar
• Friedman JI, Lindenmayer JP, Alcantara F, et al. Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. Neuropsychopharmacology. 2011 May;36(6):1289–1295.
   PubMed Web of Science ®Google Scholar
• Nielsen J, Emborg C, Gydesen S, et al. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2012;32(2):173–178.
   PubMed Web of Science ®Google Scholar
• Gunduz-Bruce H, Oliver S, Gueorguieva R, et al. Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia. Schizophr Res. 2013;143(2–3):344–347.
   PubMed Web of Science ®Google Scholar
• Muscatello MRA, Pandolfo G, Micò U, et al. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2014;34(1):129–133.
   PubMed Web of Science ®Google Scholar
• Barnes T, Leeson V, Paton C, et al. Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: the amicus study. Schizophr Bull. 2017;43(03):S165.
   Google Scholar
• Ding N, Li Z, Liu Z. Escitalopram augmentation improves negative symptoms of treatment resistant schizophrenia patients – a randomized controlled trial. Neurosci Lett. 2018;08(681):68–72.
   Google Scholar
• Lu M, Chen T, Kuo P, et al. Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: a 12-week, randomized, double-blind, placebo-controlled study. Schizophr Res. 2018;03(193):126–133.
   Google Scholar
• Fan X, Song X, Zhao M, et al. The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia. Acta Psychiatr Scand. 2017 Nov;136(5):465–472.
   PubMed Web of Science ®Google Scholar
• Weiser M, Levi L, Burshtein S, et al. Raloxifene plus antipsychotics versus placebo plus antipsychotics in severely ill decompensated postmenopausal women with schizophrenia or schizoaffective disorder: a randomized controlled trial. J Clin Psychiatry. 2017 07;78(7):e758–65.
   PubMed Web of Science ®Google Scholar
• Kelly DL, Sullivan KM, McEvoy JP, et al. Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms. J Clin Psychopharmacol. 2015;08;35(4):374–381.
   Web of Science ®Google Scholar
• Miyaoka T, Furuya M, Horiguchi J, et al. Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, multicenter, double-blind, placebo-controlled trial. Evid Based Compl Altern Med. 2015.
   PubMed Web of Science ®Google Scholar
• Ritsner MS, Bawakny H, Kreinin A. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial. Psychiatry Clin Neurosci. 2014;68(6):432–440.
   PubMed Web of Science ®Google Scholar
• Meskanen K, Ekelund H, Laitinen J, et al. A randomized clinical trial of histamine 2 receptor antagonism in treatment resistant schizophrenia. Eur Neuropsychopharmacol. 2013;23:S461.
   Web of Science ®Google Scholar
• Terevnikov V, Stenberg J, Joffe M, et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Hum Psychopharmacol. 2010;25(6):431–438.
   PubMed Web of Science ®Google Scholar
• Stenberg J, Terevnikov V, Joffe M, et al. Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia - a path model investigation. Neuropharmacology. 2013;64:248–253.
   PubMed Web of Science ®Google Scholar
• Remington G, Kapur S, Foussias G. Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2012;32(1):95–99.
   PubMed Web of Science ®Google Scholar
• Behdani F, Hebrani P, Rezaei Ardani A, et al. Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial. Arch Iran Med. 2011;14(4):270–275.
   PubMed Web of Science ®Google Scholar
• Mico’ U, Bruno A, Pandolfo G, et al. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2011;26(6):303–310.
   PubMed Web of Science ®Google Scholar
• Muscatello M, Bruno A, Pandolfo G, et al. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. J Psychopharmacol. 2011;25(5):667–674.
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Stroup TS, et al. CATIE Investigators . Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006 Apr;163(4):600–610.
   PubMed Web of Science ®Google Scholar
• Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002 Feb;159(2):255–262.
   PubMed Web of Science ®Google Scholar
• Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006 Oct;32(4):715–723.
   PubMed Web of Science ®Google Scholar
• Remington G, Agid O, Foussias G, et al. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology (Berl). 2013 Feb;225(3):505–518.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Alphs L, Green AI, et al. International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Arch Gen Psychiatry. 2003 Jan;60(1):82–91.
   PubMed Web of Science ®Google Scholar
• Wimberley T, MacCabe JH, Laursen TM, et al. Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry. 2017 Oct 1;174(10):990–998.
   PubMed Web of Science ®Google Scholar
• Ringback Weitoft G, Berglund M, Lindstrom EA, et al. Mortality, attempted suicide, re-hospitalisation and prescription refill for clozapine and other antipsychotics in Sweden-a register-based study. Pharmacoepidemiol Drug Saf. 2014 Mar;23(3):290–298.
   PubMed Web of Science ®Google Scholar
• Johnsen E, Jorgensen HA. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry. 2008 Apr 25;8(31):244X-8–31.
   PubMedGoogle Scholar
• Tollefson GD, Birkett MA, Kiesler GM, et al. Resistant Schizophrenia Study Group. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001 Jan 1;49(1):52–63.
   PubMed Web of Science ®Google Scholar
• Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and “high-dose” olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry. 2008 Mar 1;63(5):524–529.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Bobo WV, Roy A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2008 Feb;69(2):274–285.
   PubMed Web of Science ®Google Scholar
• Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry. 1998 Jul;155(7):914–920.
   PubMed Web of Science ®Google Scholar
• Naber D, Riedel M, Klimke A, et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand. 2005 Feb;111(2):106–115.
   PubMed Web of Science ®Google Scholar
• Kishi T, Suzuki T, Sekiguchi H, et al. Efficacy and tolerability of high dose olanzapine in Japanese patients with treatment-resistant schizophrenia. Asian J Psychiatr. 2013 Feb;6(1):86–87.
   PubMedGoogle Scholar
• Souza JS, Kayo M, Tassell I, et al. Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses. CNS Spectr. 2013 Apr;18(2):82–89.
   PubMed Web of Science ®Google Scholar
• Citrome L, Kantrowitz JT. Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction? Expert Rev Neurother. 2009 Jul;9(7):1045–1058.
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Volavka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008 Aug;28(4):392–400.
   PubMed Web of Science ®Google Scholar
• Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study the risperidone study group. Am J Psychiatry. 1998 Apr;155(4):499–504.
   PubMed Web of Science ®Google Scholar
• Wahlbeck K, Cheine M, Tuisku K, et al. Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):911–922.
   PubMed Web of Science ®Google Scholar
• Breier AF, Malhotra AK, Su TP, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry. 1999 Feb;156(2):294–298.
   PubMed Web of Science ®Google Scholar
• Azorin JM, Spiegel R, Remington G, et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry. 2001 Aug;158(8):1305–1313.
   PubMed Web of Science ®Google Scholar
• Sacchetti E, Galluzzo A, Valsecchi P, et al., MOZART Study Group. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res. 2009 Aug;113(1):112–121.
   PubMed Web of Science ®Google Scholar
• Kane JM, Khanna S, Rajadhyaksha S, et al. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2006 Jan;21(1):21–28.
   PubMed Web of Science ®Google Scholar
• Kane JM, Meltzer HY, Carson WH, et al. Aripiprazole Study Group. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry. 2007 Feb;68(2):213–223.
   PubMed Web of Science ®Google Scholar
• Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine (‘seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol. 2000 May;15(3):121–131.
   PubMed Web of Science ®Google Scholar
• Lal S, Thavundayil JX, Nair NP, et al. Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial. J Psychiatry Neurosci. 2006 Jul;31(4):271–279.
   PubMed Web of Science ®Google Scholar
• Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry. 2017 Nov;62(11):772–777.
   PubMed Web of Science ®Google Scholar
• Correll CU, Rubio JM, Inczedy-Farkas G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry. 2017 Jul 1;74(7):675–684.
   PubMed Web of Science ®Google Scholar
• Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf. 2003 Jan-Feb;12(1):41–48.
   PubMed Web of Science ®Google Scholar
• Taylor DM, Smith L, Gee SH, et al. Augmentation of clozapine with a second antipsychotic - a meta-analysis. Acta Psychiatr Scand. 2012 Jan;125(1):15–24.
   PubMed Web of Science ®Google Scholar
• Sommer IE, Begemann MJ, Temmerman A, et al. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull. 2012 Sep;38(5):1003–1011.
   PubMed Web of Science ®Google Scholar
• Barbui C, Signoretti A, Mule S, et al. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull. 2009 Mar;35(2):458–468.
   PubMed Web of Science ®Google Scholar
• Porcelli S, Balzarro B, Serretti A. Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol. 2012 Mar;22(3):165–182.
   PubMed Web of Science ®Google Scholar
• Galling B, Roldan A, Hagi K, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017 Feb;16(1):77–89.
   PubMed Web of Science ®Google Scholar
• Ortiz-Orendain J, Castiello-de Obeso S, Colunga-Lozano LE, et al. Antipsychotic combinations for schizophrenia. Cochrane Database Syst Rev. 2017 Jun;28(6):CD009005.
   Google Scholar
• Barber S, Olotu U, Corsi M, et al. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database Syst Rev. 2017 Mar;23(3):CD006324.
   Google Scholar
• Galling B, Roldan A, Rietschel L, et al. Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opin Drug Saf. 2016 May;15(5):591–612.
   PubMed Web of Science ®Google Scholar
• Zheng W, Xiang YT, Yang XH, et al. Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a meta-analysis of randomized controlled trials. J Clin Psychiatry. 2017 May;78(5):e498–505.
   PubMed Web of Science ®Google Scholar
• Tracy DK, Joyce DW, Sarkar SN, et al. Skating on thin ice: pragmatic prescribing for medication refractory schizophrenia. BMC Psychiatry. 2015 Jul;25;15(174):015–0559-x.
   Google Scholar
• Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2009 Apr;109(1–3):10–14.
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Jarskog LF, Fleischhacker WW. New therapeutic approaches for treatment-resistant schizophrenia: a look to the future. J Psychiatr Res. 2014 Nov;58:1–6.
   PubMed Web of Science ®Google Scholar
• Citrome L. Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? Expert Rev Neurother. 2009 Jan;9(1):55–71.
   PubMed Web of Science ®Google Scholar
• Helfer B, Samara MT, Huhn M, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry. 2016 Sep 1;173(9):876–886.
   PubMed Web of Science ®Google Scholar
• Galling B, Vernon JA, Pagsberg AK, et al. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatr Scand. 2018 Mar;137(3):187–205.
   PubMed Web of Science ®Google Scholar
• Bugarski-Kirola D, Blaettler T, Arango C, et al. Bitopertin in negative symptoms of schizophrenia-results from the phase III FlashLyte and DayLyte studies. Biol Psychiatry. 2017 Jul 1;82(1):8–16.
   PubMed Web of Science ®Google Scholar
• Goff DC, Lamberti JS, Leon AC, et al. A placebo-controlled add-on trial of the ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2008 Feb;33(3):465–472.
   PubMed Web of Science ®Google Scholar
• Strzelecki D, Urban-Kowalczyk M, Wysokinski A. Serum levels of interleukin 6 in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study). Hum Psychopharmacol. 2018 Mar;33(2):e2652.
   PubMed Web of Science ®Google Scholar
• Tsai GE, Lin PY. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des. 2010;16(5):522–537.
   PubMed Web of Science ®Google Scholar
• Javitt DC, Duncan L, Balla A, et al. Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry. 2005 Mar;10(3):275–287.
   PubMed Web of Science ®Google Scholar
• Veerman SR, Schulte PF, Smith JD, et al. Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. Psychol Med. 2016 Jul;46(9):1909–1921.
   PubMed Web of Science ®Google Scholar
• Solmi M, Veronese N, Thapa N, et al. Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS Spectr. 2017 Oct;22(5):415–426.
   PubMed Web of Science ®Google Scholar
• Lundbeck H. A/S; Positron Emission Tomography (PET) study investigating dopamine and serotonin receptor occupancy after multiple oral dosing of Lu AF35700. In: ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2018 Aug 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT02333487 NLM Identifier: NCT02333487.
   Google Scholar
• Lundbeck Press Release. Lundbeck starts clinical phase III program with Lu AF35700 in patients with treatment resistant schizophrenia. cited cited Aug 9, 2018]. Available from: http://investor.lundbeck.com/news-releases/news-release-details/lundbeck-starts-clinical-phase-iii-program-lu-af35700-patients
   Google Scholar
• Davidson M, Saoud J, Staner C, et al. Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. Am J Psychiatry. 2017 Dec 1;174(12):1195–1202.
   PubMed Web of Science ®Google Scholar
• Fellner C. New schizophrenia treatments address unmet clinical needs. P T. 2017 Feb;42(2):130–134.
   PubMedGoogle Scholar
• Ballester J, Frankel B. Pharmacological advances in the treatment of schizophrenia. Am J Psychiatry Residents J. 2017 May;(11):5–8.
   Google Scholar
• Farooq S, Agid O, Foussias G, et al. Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification. Schizophr Bull. 2013 Nov;39(6):1169–1172.
   PubMed Web of Science ®Google Scholar
• McEvoy JP. Use of clozapine in schizophrenia. JAMA Psychiatry. 2016 Oct 1;73(10):1097–1098.
   PubMedGoogle Scholar
• Correll C, Brevig T, Brain C Burden and pharmacotherapy of treatment-resistant schizophrenia: a survey among US psychiatrists. In: 2018 May 5–9; American Psychiatric Association Annual Meeting, New York, NY. 2018
   Google Scholar
• Verdoux H, Quiles C, Bachmann CJ, et al. Prescriber and institutional barriers and facilitators of clozapine use: a systematic review. Schizophr Res. 2018 Jun 4.   pii: S0920-9964(18)30311-6. doi:10.1016/j.schres.2018.05.046 [Epub ahead of print].
   Google Scholar
• Shah P, Iwata Y, Plitman E, et al. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: a systematic review. Psychiatry Res. 2018 Jul;9(268):114–122.
   Google Scholar
• Citrome L, McEvoy JP, Saklad SR. Guide to the management of clozapine-related tolerability and safety concerns. Clin Schizophr Relat Psychoses Fall. 2016;10(3):163–177.
   PubMedGoogle Scholar
• Citrome L, Holt RI, Walker DJ, et al. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig. 2011;31(7):455–482.
   PubMed Web of Science ®Google Scholar